Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY von Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao‐Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin‐Yuan, Visseren‐Grul, Carla, Frimodt‐Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Be... von PATEL, Jyoti D, SOCINSKI, Mark A, GUBA, Susan C, JINGYI LIU, FRIMODT-MOLLER, Bente, JOHN, William J, OBASAJU, Coleman K, PENNELLA, Eduardo J, BONOMI, Philip, GOVINDAN, Ramaswamy, GARON, Edward B, REYNOLDS, Craig H, SPIGEL, David R, OLSEN, Mark R, HERMANN, Robert C, JOTTE, Robert M, BECK, Thaddeus, RICHARDS, Donald A

Volltext

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, pl... von Urba, Susan, van Herpen, Carla M L, Sahoo, Tarini Prasad, Shin, Dong M, Licitra, Lisa, Mezei, Klara, Reuter, Christoph, Hitt, Ricardo, Russo, Francesca, Chang, Shao-Chun, Hossain, Anwar M, Frimodt-Moller, Bente, Koustenis, Andrew, Hong, Ruey-Long

Volltext

Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer von CHAN, Stephen, ROMIEU, Gilles, MAYORDOMO, Jose Ignacio, ANTON, Antonio, HARRISON, Mark, JONES, Alison, CARRASCO, Eva, THAREAU VAURY, A, FRIMODT-MOLLER, Bente, FUMOLEAU, Pierre, HUOBER, Jens, DELOZIER, Thierry, TUBIANA-HULIN, Michele, SCHNEEWEISS, Andreas, LLUCH, Ana, LLOMBART, Antonio, DU BOIS, Andreas, KREIENBERG, Rolf

Volltext

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer von Urba, Susan, van Herpen, Carla M. L., Sahoo, Tarini Prasad, Shin, Dong M., Licitra, Lisa, Mezei, Klara, Reuter, Christoph, Hitt, Ricardo, Russo, Francesca, Chang, Shao‐Chun, Hossain, Anwar M., Frimodt‐Moller, Bente, Koustenis, Andrew, Hong, Ruey‐Long

Volltext

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset von Nishio, Kazuto, Seto, Takashi, Nishio, Makoto, Reck, Martin, Garon, Edward B., Sakai, Kazuko, Goto, Koichi, Kato, Terufumi, Nakanishi, Yoichi, Takahashi, Toshiaki, Yamamoto, Nobuyuki, Kiura, Katsuyuki, Ohe, Yuichiro, Tamura, Tomohide, Visseren-Grul, Carla, Frimodt-Moller, Bente, Hozak, Rebecca R., Wijayawardana, Sameera R., Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC von Le, Xiuning, Nilsson, Monique, Goldman, Jonathan, Reck, Martin, Nakagawa, Kazuhiko, Kato, Terafumi, Ares, Luis Paz, Frimodt-Moller, Bente, Wolff, Katharina, Visseren-Grul, Carla, Heymach, John V., Garon, Edward B.

Volltext

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial von Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Chiu, Chao-Hua, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin, Chu, Quincy, Pujol, Jean-Louis, Moro-Sibilot, Denis, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Kim, Young Hak, Kurata, Takayasu, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Atagi, Shinji, Azuma, Koichi, Horio, Yoshitsugu, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Kaneda, Hiroyasu, Tomii, Keisuke, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Kim, Sang-We, Min, Young Joo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Lin, Meng-Chih, Su, Wu-Chou, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Acoba, Jared, Garon, Edward, Jung, Gabriel

Volltext

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer von Nakagawa, Kazuhiko, Nadal, Ernest, Garon, Edward B., Nishio, Makoto, Seto, Takashi, Yamamoto, Nobuyuki, Park, Keunchil, Shih, Jin-Yuan, Paz-Ares, Luis, Frimodt-Moller, Bente, Zimmermann, Annamaria H., Wijayawardana, Sameera, Visseren-Grul, Carla, Reck, Martin

Volltext

Abstract CT160: Safety of selpercatinib for RET -altered advanced solid tumors: a post hoc analysis of LIBRETTO-001 von Bauer, Todd M, Besse, Benjamin, Loong, Herbert H F, Robinson, Bruce, Soldatenkova, Victoria, Muehlenbein, Catherine Elizabeth, Frimodt-Moller, Bente, McCoach, Caroline E

Volltext

Ramucirumab or placebo plus erlotinib inEGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY von Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao-Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin-Yuan, Visseren-Grul, Carla, Frimodt-Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cance... von Nadal, Ernest, Horinouchi, Hidehito, Shih, Jin-Yuan, Nakagawa, Kazuhiko, Reck, Martin, Garon, Edward B., Wei, Yu-Feng, Kollmeier, Jens, Frimodt-Moller, Bente, Barrett, Emily, Lipkovich, Olga, Visseren-Grul, Carla, Novello, Silvia

Volltext

RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC von Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Nishio, Makoto, Aix, Santiago Ponce, Paz-Ares, Luis, Chiu, Chao-Hua, Park, Keunchil, Novello, Silvia, Nadal, Ernest, Nishino, Kazumi, Yoh, Kiyotaka, Shih, Jin-Yuan, Chik, Jeannie Yk, Moro-Sibilot, Denis, Puri, Tarun, Varughese, Sunoj Chacko, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin

Volltext

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer von Besse, Benjamin, Barlesi, Fabrice, Demedts, Ingel, Fuentes Pradera, Jose, Robinet, Gilles, Gazzah, Anas, Soldatenkova, Victoria, Frimodt-Moller, Bente, Kim, Jong Seok, Vansteenkiste, Johan

Volltext

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY (vol 111, pg 4510, 2020) von Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao-Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin-Yuan, Visseren-Grul, Carla, Frimodt-Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer von Besse, Benjamin, Barlesi, Fabrice, Demedts, Ingel, Pradera, Jose Fuentes, Robinet, Gilles, Gazzah, Anas, Soldatenkova, Victoria, Frimodt-Moller, Bente, Kim, Jong Seok, Vansteenkiste, Johan

Volltext

PS1-2RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset von Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B, Chiu, Chao-Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin-Yuan, Visseren-Grul, Carla, Frimodt-Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset von Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao-Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin-Yuan, Visseren-Grul, Carla, Frimodt-Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko

Volltext

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR Clinical von Besse, Benjamin, Vansteenkiste, Johan, Renault, Patrick-Aldo, Frimodt-Moller, Bente, Chao, Grace, Gil, Maciej, Barlesi, Fabrice

Volltext

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) von Besse, Benjamin, Vansteenkiste, Johan, Renault, Patrick-Aldo, Frimodt-Moller, Bente, Chao, Grace, Gil, Maciej, Barlesi, Fabrice

Volltext